• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Incidences of Herpes Zoster and Acne by Age in Japanese Patients With Atopic Dermatitis During Treatment With Baricitinib or Upadacitinib: A Single-Centre Retrospective Study.

作者信息

Watanabe Ayu, Kamata Masahiro, Okada Yoshiki, Tomura Yayoi, Tada Yayoi

机构信息

Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.

出版信息

Exp Dermatol. 2025 Apr;34(4):e70100. doi: 10.1111/exd.70100.

DOI:10.1111/exd.70100
PMID:40223460
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11995142/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f761/11995142/791195454d8b/EXD-34-e70100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f761/11995142/791195454d8b/EXD-34-e70100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f761/11995142/791195454d8b/EXD-34-e70100-g001.jpg

相似文献

1
Incidences of Herpes Zoster and Acne by Age in Japanese Patients With Atopic Dermatitis During Treatment With Baricitinib or Upadacitinib: A Single-Centre Retrospective Study.巴瑞替尼或乌帕替尼治疗期间日本特应性皮炎患者带状疱疹和痤疮的年龄别发病率：一项单中心回顾性研究
Exp Dermatol. 2025 Apr;34(4):e70100. doi: 10.1111/exd.70100.
2
Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib.预测接受乌帕替尼治疗的特应性皮炎患者发生带状疱疹的背景因素。
J Dermatol. 2023 Oct;50(10):1301-1312. doi: 10.1111/1346-8138.16879. Epub 2023 Jul 3.
3
A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.一项在日本开展的3期随机、多中心、双盲研究，旨在评估乌帕替尼联合外用皮质类固醇激素治疗中度至重度特应性皮炎青少年及成年患者的安全性（Rising Up）：一项24周中期分析。
JAAD Int. 2021 Dec 20;6:27-36. doi: 10.1016/j.jdin.2021.11.001. eCollection 2022 Mar.
4
Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.特应性皮炎患者发生痤疮的风险与使用系统性Janus激酶抑制剂治疗之间的关联：一项系统评价和荟萃分析
Inflamm Res. 2023 Sep;72(9):1861-1871. doi: 10.1007/s00011-023-01789-x. Epub 2023 Sep 14.
5
Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan.在中度至重度特应性皮炎患者中，从巴瑞替尼4毫克转换为乌帕替尼30毫克的有效性：日本的一项真实世界临床实践。
J Dermatolog Treat. 2023 Dec;34(1):2276043. doi: 10.1080/09546634.2023.2276043. Epub 2023 Dec 10.
6
Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study.在3期Rising Up研究中接受乌帕替尼治疗的日本特应性皮炎患者中的痤疮情况
Dermatol Ther (Heidelb). 2023 Aug;13(8):1817-1830. doi: 10.1007/s13555-023-00961-9. Epub 2023 Jun 25.
7
A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis.澳大利亚真实世界中使用乌帕替尼治疗重度特应性皮炎的经验。
Australas J Dermatol. 2023 Nov;64(4):e352-e356. doi: 10.1111/ajd.14139. Epub 2023 Jul 31.
8
Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.Janus激酶抑制剂治疗特应性皮炎：一项荟萃分析的汇总评价
Front Immunol. 2024 Feb 23;15:1342810. doi: 10.3389/fimmu.2024.1342810. eCollection 2024.
9
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.阿巴西普、巴瑞替尼和乌帕替尼治疗中重度特应性皮炎的疗效和安全性比较：一项网络荟萃分析。
Dermatol Ther. 2022 Sep;35(9):e15636. doi: 10.1111/dth.15636. Epub 2022 Jul 27.
10
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.度普利尤单抗联合局部皮质类固醇治疗青少年和成人中重度特应性皮炎（AD Up）的安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的结果。
Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.

引用本文的文献

1
Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis Patients over and under 65 Years of Age: A Real-World Comparative Analysis.三种 Janus 激酶抑制剂在 65 岁及以上和 65 岁以下溃疡性结肠炎患者中的疗效与安全性：一项真实世界的比较分析。
Inflamm Intest Dis. 2025 Jun 24;10(1):180-186. doi: 10.1159/000546640. eCollection 2025 Jan-Dec.

本文引用的文献

1
Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study.在3期Rising Up研究中接受乌帕替尼治疗的日本特应性皮炎患者中的痤疮情况
Dermatol Ther (Heidelb). 2023 Aug;13(8):1817-1830. doi: 10.1007/s13555-023-00961-9. Epub 2023 Jun 25.
2
Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence.基于当前证据的特应性皮炎中JAK抑制剂和生物制剂的最佳应用
JID Innov. 2023 Feb 24;3(3):100195. doi: 10.1016/j.xjidi.2023.100195. eCollection 2023 May.
3
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
乌帕替尼在日本类风湿关节炎患者中的安全性特征。
Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27.